Abstract
The aim of this study was to investigate the role of positron emission tomography (PET) with [18F]fluoro-2-deoxyglucose (18FDG) in metastatic testicular germ cell tumours. Twenty-one patients with stage II–IV testicular germ cell tumours were imaged by PET with a multiwire proportional chamber PET system and18FDG. Avid18FDG uptake was seen in metastatic disease from primary seminoma and malignant teratoma. Normal tissue uptake was seen in differentiated teratoma or necrotic, fibrotic tissue.18FDG standard uptake values and tumour to normal tissue ratios were 6.0±1.4 and 1.7±0.4 (mean ± 1SD), respectively, for malignant tissue. Reduction of18FDG tumour to normal tissue ratios from pre-treatment to on-treatment scans was predictive of response (n=3). No significant reduction in18FDG uptake was seen in patients not responding to therapy (n=2). These results suggest a role for18FDG PET in the detection and management of metastatic testicular germ cell tumours.
Similar content being viewed by others
References
Mostofi FK, Sobin LH.International histological classification of tumours of the testes (no. 16). Geneva: WHO, 1977.
Horwich A, Testicular germ cell tumours: an introductory overview. In: Horwich A, ed.Investigation and management of testicular cancer. 1st edn. London: Chapman Hall Medical; 1991:1–13.
Einhorn L. Treatment of testicular cancer: a new improved model.J Clin Oncol 1990; 8: 1777–1781.
Peckham MJ, Horwich A, Hendrey WF, et al. Advanced seminoma treatment with cis-platinum-based combination chemotherapy or carboplatin (JMR8).Br J Cancer 1985; 52: 7–13.
Mason MD. Tumour markers. In: Horwich A, ed.Investigation and management of testicular cancer, 1st edn. London: Chapman Hall Medical; 1991: 33–50.
Kausitz J, Ondrus D, Belan V, Matoska J. Monitoring of patients with non-seminomatous germ cell tumours of the testis by determination of alpha-fetoprotein and beta-human chorionic gonadotrophin levels and by computed tomography.Neoplasma 1992; 39: 357–361.
Bajorin D, Herr H, Motzer R, Bosl G. Current perspectives on the role of adjuvant surgery in combined modality treatment for patients with germ cell tumours.Semin Oncol 1992; 19: 148–158.
Di Chiro G. Positron emission tomography using [18F]-fluorodeoxyglucose in brain tumours; a powerful diagnostic and prognostic tool.Invest Radiol 1986; 22: 360–371.
Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991, 32: 623–648.
Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.Radiology 1993; 188: 487–490.
Goldberg MA, Lee MJ, Fischman AJ, et al. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.Radiographics 1993; 13: 1047–1062.
Hoekstra O, Ossenkoppele G, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.J Nucl Med 1993; 34: 1706–1710.
Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy.J Nucl Med 1993; 34: 12–17.
Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.J Clin Oncol 1993; 11: 2101–2111.
Ott RJ, Marsden PK, Flower MA, et al. Clinical PET with a large area multiwire proportional chamber PET camera.Nucl Instr Methods 1988; A269: 436–442.
Ott RJ. Wire chambers revisited.Eur J Nucl Med 1993; 20: 348–358.
Deehan BJ, Flower MA, Ott RJ, et al. Correcting for scatter and absorption in 3-D images obtained from a large area positron camera: a comparison of methods.Nucl Med Commun 1994; 15: 237
Marsden PK, Ott RS, Bateman JE, et al. The performance of a multiwire proportional chamber positron camera for clinical use.Phys Med Biol 1989; 34: 1043–1062.
Robb RA. A software system for interactive and quantitative analysis of medical images. In: Höhne KH, Fuchs H, Pizer SM.3D imaging in medicine. NATO ASI series Vol. F 60; 1990: 333–361.
Woodward HQ, Gigler RE, Freed B, et al. Expression of tissue isotope distribution.J Nucl Med 1975; 16: 958–959.
Wahl RL, Greenough R, Clarke MF, et al. Initial evaluation of FDG/PET imaging of metastatic testicular neoplasms.J Nucl Med 1993; 35: 6.
Beets G, Pennincks F, Schiepers C, et al. Clinical value of whole body positron emission tomography in with [18F]fluorodeoxyglucose in recurrent colorectal cancer.Br J Surg 1994; 81: 1666–1670.
Lewis P, Griffin S, Marsden P, et al. Whole body F-18 fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer.Lancet 1994; 344: 1265–1266.
Rege S, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.Cancer 1993; 72: 82–90.
Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon- 11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study.J Nucl Med 1990; 32: 1211–1218.
Kubota K, Yamada K, Yoshioka S, et al. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose.Clin Nucl Med 1991; 17: 361–363.
Jansen RL, Sylvester R, Sleyfer DT, et al. Long term follow up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post chemotherapy.Eur J Cancer 1991; 27: 695–698.
Logothesis CJ, Samuels ML, Trindade A, et al. The growing teratoma syndrome.Cancer 1990; 50: 1629–1635.
Toner GC, Panieek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for non-seminomatous germ cell tumours: recommendations for patient selection.J Clin Oncol 1990; 8: 1683–1694.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilson, C.B., Young, H.E., Ott, R.J. et al. Imaging metastatic testicular germ cell tumours with18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 22, 508–513 (1995). https://doi.org/10.1007/BF00817273
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00817273